Montreux Equity Partners is a private investment firm dedicated to building the leading healthcare companies of tomorrow.
Business Model:
Revenue: $15.9M
Employees: 51-200
Address: 4 Embarcadero Center
City: San Francisco
State: CA
Zip: 94111
Country: US
Founded in 1993, Montreux Equity Partners is a private investment firm focused on making growth capital investments in the leading companies of tomorrow. Our portfolio companies address the most compelling domestic and global trends in health. We are currently investing out of our fifth fund. We focus on commercial stage companies that possess highly differentiated products, technologies, and services. At the time of investment, a company will typically have $5 to $50 million in revenues. Our capital fuels product expansion, new market entry, and strategic acquisitions.
Contact Phone:
+16502341200
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2007 | Pulmonx | Series B | 20M |
7/2016 | GC Aesthetics | Series D | 0 |
4/2012 | Epirus Biopharmaceuticals | Venture Round | 8.1M |
7/2022 | Tebra | Series B | 0 |
6/2000 | NeurogesX | Series A | 8.4M |
3/2005 | Novalar Pharmaceuticals | Series C | 27M |
2/2014 | GC Aesthetics | Private Equity Round | 60M |
12/2005 | NeurogesX | Series D | 20M |
1/2004 | Peninsula Pharmaceuticals | Series C | 0 |
2/2000 | PartnerGate | Series A | 17.5M |
3/2022 | FinPay | Series D | 0 |
6/2004 | ARYx Therapeutics | Series D | 55M |
5/2015 | SI-BONE | Growth | 21M |
4/2007 | NovaCardia | Series B | 18M |
12/2001 | Marketwired | Venture Round | 0 |
11/2007 | Novalar Pharmaceuticals | Series D | 30M |
9/2007 | Sequel Pharmaceuticals | Series A | 20M |
10/2008 | MAKO Surgical | Post-IPO Equity | 60M |
4/2000 | Internet Generation Storage | Venture Round | - |
11/2011 | Pivot Medical | Series C | 32M |
8/2008 | Glaukos | Series D | 35M |
12/2009 | moksha8 Pharmaceuticals | Series B | 25.1M |
5/2005 | Bayhill Therapeutics | Series B | 35.4M |
3/2007 | Transcept Pharmaceuticals | Series D | 40M |
6/2022 | KEO World | Venture Round | 0 |
10/2002 | Peninsula Pharmaceuticals | Series B | 0 |
2/2004 | NeurogesX | Series C | 35M |
8/2005 | KFx Medical | Series A | 6.2M |
12/2005 | Asthmatx | Series C | 27M |
6/2016 | SI-BONE | Venture Round | 26M |
9/2007 | Novalar Pharmaceuticals | Series D | 30M |
4/2006 | Bayhill Therapeutics | Venture Round | 15.8M |
4/2005 | Orexigen Therapeutics | Series B | 35M |
7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
5/2014 | Pure Life Renal | Series A | 20M |
7/2004 | SkinMedica | Series D | 30M |
4/2005 | SkinMedica | Series E | 0 |
4/2006 | SkinMedica | Series E | 0 |
2/2013 | Glaukos | Series F | 30M |
2/2011 | Glaukos | Series E | 0 |
2/2014 | Mindbody Business | Private Equity Round | 50M |
6/2004 | Somaxon Pharmaceuticals | Series B | 23M |
3/2010 | Pulmonx | Series C | 0 |
1/2012 | Pulmonx | Private Equity Round | 0 |
7/2015 | Kareo | Series G | 55.4M |
5/2019 | Pulmonx | Series G | 0 |
6/2009 | NovoStent Corporation | Venture Round | 1.1M |
2/2007 | Pivot Medical | Series A | 2M |
9/2011 | SI-BONE | Venture Round | 16M |
11/2020 | FinPay | Series C | 5M |
6/2010 | Avantis Medical Systems | Debt Financing | 2.8M |
6/2013 | Colorescience | Series A | 10M |
9/2006 | NovaCardia | Series B | 48M |
8/2007 | Tobira Therapeutics | Series A | 31M |
7/2017 | Colorescience | Series C | 15M |
4/2005 | NovaCardia | Series A | - |
4/2014 | SI-BONE | Venture Round | 33M |
10/2018 | GC Aesthetics | Equity | 97M |
10/2010 | GC Aesthetics | Venture Round | 30M |
7/2012 | Epirus Biopharmaceuticals | Venture Round | 5M |
3/2018 | Sonoma Pharmaceuticals | Post-IPO Equity | 4.6M |
4/2014 | Epirus Biopharmaceuticals | Series B | 36M |
10/2020 | TigerConnect | Series D | 0 |
5/2019 | Crown Laboratories | Private Equity Round | - |
3/2002 | PartnerGate | Venture Round | 4M |
12/2007 | Pivot Medical | Series B | 0 |
1/2000 | Cephren | Venture Round | 41.5M |
9/2003 | Marketwired | Series D | 0 |
8/2007 | KFx Medical | Series B | 10M |
6/2005 | Verus Pharmaceuticals | Series A | 0 |
11/1990 | Marketwired | Series A | 17.6M |
8/2005 | Cerexa Inc. | Series A | 0 |
12/2003 | Pulmonx | Series A | 7.1M |
8/2004 | Avera Pharmaceutical | Series C | 0 |
1/2002 | NeurogesX | Series B | 22.9M |
11/2006 | Avantis Medical Systems | Series B | 12M |
9/2010 | Tobira Therapeutics | Series B | 31M |
6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
4/2000 | StorageWay | Venture Round | 12M |
7/2022 | Tebra | Series B | 0 |
6/2022 | KEO World | Venture Round | 0 |
3/2022 | FinPay | Series D | 0 |
11/2020 | FinPay | Series C | 0 |
10/2020 | TigerConnect | Series D | 0 |
5/2019 | Pulmonx | Series G | 0 |
5/2019 | Crown Laboratories | Private Equity Round | - |
10/2018 | GC Aesthetics | Venture Round | 0 |
3/2018 | Sonoma Pharmaceuticals | Post-IPO Equity | 0 |
7/2017 | Colorescience | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|